StockData
Connect Biopharma Holdings Ltd logo

Connect Biopharma Holdings Ltd (CNTB) company profile

CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.58−0.06 (-9.98%)

Close on Nov 17, 2026Market cap $36.45MP/E –Yield –

About Connect Biopharma

Pharmaceutical Preparations, SIC 2834

Connect Biopharma is a clinical-stage biotechnology company that develops antibody therapies for inflammatory respiratory diseases. The company focuses on developing its lead drug candidate, rademikibart, an antibody targeting interleukin-4 receptor alpha. Rademikibart is in clinical development for treating acute exacerbations of asthma and chronic obstructive pulmonary disease, as well as for chronic treatment of these pulmonary conditions and atopic dermatitis. Its potential end-users are patients who suffer from these respiratory and inflammatory skin disorders.

The company is based in San Diego, California. It does not own or operate manufacturing facilities, instead relying on third-party contract manufacturers for raw materials and supplies. Connect Biopharma partners with Simcere Pharmaceutical to develop and commercialize rademikibart in Greater China, while maintaining rights in other global markets. Clinical trials for its drug candidate have taken place across several countries, including the United States, Poland, Hungary, China, South Korea, Australia, and New Zealand.

Summary of the business section of Connect Biopharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Connect Biopharma Holdings Ltd
Headquarters
San Diego, CA
Address
3580 Carmel Mountain Road, Suite 200 92130
Phone
(858) 727-1040
Industry
Pharmaceutical Preparations
Incorporated in
E9
Fiscal year ends
December 31
Auditor
CBIZ CPAs P.C, New York, NY

Stock & identifiers

Ticker
CNTB
Exchange
Nasdaq
IPO date
Mar 19, 2021
Shares outstanding
63M, Jul 31, 2026
Public float
$40.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1835268
CUSIP
207523101
ISIN
US2075231017
FIGI
BBG00ZGYNJ49
Share class FIGI
BBG00ZGYNJZ5
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Barry D. QuartChief Executive Officer, Director224,034
Lisa PerazaSenior Vice President, Finance45,189
David Leslie SzekeresPresident215,739
Jean I. LiuDirector20,763
Kleanthis Gabriel XanthopoulosDirector91,554
James HuangDirector13,310,000
James A. SchoeneckDirector–
Karen J. WilsonDirector10,000

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 19, 2021
Offer price
$17.00
Securities offered
11,250,000
Gross proceeds
$191.25M
Exchange
Nasdaq
First trading day
Mar 19, 2021
First-day close
$18.49+8.8%
Lock-up ends (est.)
Sep 15, 2021

“PER ADS TOTAL Initial public offering price $ 17.00 $ 191,250,000 Underwriting discounts and commissions (1) $ 1.19 $ 13,387,500 Proceeds to Connect Biopharma Holdings Limited, before expenses $ 15.81 $ 177,862,500 (1) See “Underwriting” for additional information regarding underwriting compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?